Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a two-part clinical study. Part A: Multisite MRI Acquisition - Protocol Harmonization Part B: Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a clinical study

Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a two-part clinical study. Part A: Multisite MRI Acquisition - Protocol Harmonization Part B: Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a clinical study - PharmaCog

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38870

Enrollment

Registered

2013-05-22

Start date

2013-06-26

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment objective memory impairment without dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with a diagnosis of Mild Cognitive Impairment, aged 55-90 years and memory complaints verified by a physician and on cognitive testing.

Exclusion criteria

Exclusion criteria: Ischaemic lesions Head injury with loss of consciousness > 24 hours Current substance abuse or therapy with steroids or chemotherapy Systemic disease with frequent involvement of the CNS CNS disease diagnosed or in treatment Inadequate for neuropsychological testing Enrolment in other trials/studies not compatible with this study Use of specific medication (History of) neurological/psychiatric illnesses Ferromagnetic implants and devices not eligible for MRI scanning

Design outcomes

Primary

Measure	Time frame
Changes of the hippocampal volume between the two groups (CSFP and CSFN) and within the same group over time.	—

Secondary

Measure	Time frame
* Neuropsychological progression and conversion to dementia. * Change in structural, functional, neurophysiological, biochemical biomarkers and their combination, i.e. MATRIX and their correlation with change in cognition and hippocampal volume.	—

Countries

Netherlands

Outcome results